health canada approval zepbound tirzepatide obesity canada 2024 2025 has approved Wegovy® (semaglutide) for the treatment of MASH (non-cirrhotic metabolic dysfunction-associated steatohepatitis) — a serious liver disease that is one of many downstream conditions related to obesity. As many Pharmacotherapy for obesity management in

All individuals were infected with SARS-CoV-2 Wuhan viral strain in 2020, which was confirmed by PCR at University of Alberta Hospital, Edmonton

Prescriptions for semaglutide and tirzepatide among patients with PCOS Between 2021 and 2025, 445,258 patients with PCOS had at least one medical encounter, of whom 90,206 (20.3%) received a semaglutide or tirzepatide prescription during the study period

10.1093/gastro/goab053 Gastroenterol Rep

This pharmacological advantage explains why weight loss on tirzepatide often outpaces results from diet-only approaches

Through a collaborative consultation, we help you explore options like Semaglutide or Tirzepatide, guiding you to the perfect solution for sustainable, healthy weight loss.

Clinical trials of drugs discovered or developed by Purdue faculty are being tested in more than 1,600 research hospitals/clinics around the world